WO2015181555A8 - Expression profiling for determining the responsiveness of cancers to treatment with an anti-angiogenic agent - Google Patents

Expression profiling for determining the responsiveness of cancers to treatment with an anti-angiogenic agent Download PDF

Info

Publication number
WO2015181555A8
WO2015181555A8 PCT/GB2015/051557 GB2015051557W WO2015181555A8 WO 2015181555 A8 WO2015181555 A8 WO 2015181555A8 GB 2015051557 W GB2015051557 W GB 2015051557W WO 2015181555 A8 WO2015181555 A8 WO 2015181555A8
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
responsiveness
determining
cancers
treatment
Prior art date
Application number
PCT/GB2015/051557
Other languages
French (fr)
Other versions
WO2015181555A1 (en
Inventor
Denis Paul Harkin
Richard Kennedy
Andrena MCCAVIGAN
Katherine KEATING
Laura Hill
Steve Deharo
Timothy Davison
Fionnuala Patterson
Sinead DONEGAN
Gera JELLEMA
Charlie GOURLEY
Original Assignee
Almac Diagnostics Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almac Diagnostics Limited filed Critical Almac Diagnostics Limited
Priority to EP15727055.4A priority Critical patent/EP3149196A1/en
Priority to US15/311,618 priority patent/US20170088902A1/en
Publication of WO2015181555A1 publication Critical patent/WO2015181555A1/en
Publication of WO2015181555A8 publication Critical patent/WO2015181555A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a cancer sub-type. Provided are methods for determining clinical prognosis of a subject with cancer, selecting whether to administer an anti-angiogenic therapeutic agent to a subject with cancer and predicting responsiveness of a subject with cancer to an anti-angiogenic therapeutic agent. The methods are based on assessing from the expression level of biomarkers disclosed herein whether the cancer belongs to the sub- type. Companion methods of treating cancer and agents for use in treating cancer are also provided.
PCT/GB2015/051557 2014-05-28 2015-05-28 Expression profiling for cancers treated with anti-angiogenic therapy WO2015181555A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP15727055.4A EP3149196A1 (en) 2014-05-28 2015-05-28 Expression profiling for cancers treated with anti-angiogenic therapy
US15/311,618 US20170088902A1 (en) 2014-05-28 2015-05-28 Expression profiling for cancers treated with anti-angiogenic therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1409476.7A GB201409476D0 (en) 2014-05-28 2014-05-28 Molecular subtype for use in prognosis
GB1409476.7 2014-05-28

Publications (2)

Publication Number Publication Date
WO2015181555A1 WO2015181555A1 (en) 2015-12-03
WO2015181555A8 true WO2015181555A8 (en) 2016-01-28

Family

ID=51177579

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2015/051557 WO2015181555A1 (en) 2014-05-28 2015-05-28 Expression profiling for cancers treated with anti-angiogenic therapy

Country Status (4)

Country Link
US (1) US20170088902A1 (en)
EP (1) EP3149196A1 (en)
GB (1) GB201409476D0 (en)
WO (1) WO2015181555A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3362087A1 (en) * 2015-10-15 2018-08-22 The Scripps Research Institute BINDING ACTIVITY OF AMINOACYL-tRNA SYNTHETASE IN CHARCOT-MARIE-TOOTH (CMT) NEUROPATHY AND CMT-RELATED NEUROLOGICAL DISEASES
WO2021034091A1 (en) * 2019-08-19 2021-02-25 재단법인 아산사회복지재단 Method for diagnosing glioblastoma
WO2021156137A1 (en) * 2020-02-04 2021-08-12 Oslo Universitetssykehus Hf Biomarkers predicting clinical response of a vegf-a inhibitory drug in cancer patients, method for their selection and use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201691257A1 (en) * 2011-06-02 2017-02-28 Олмак Дайэгностикс Лимитед MOLECULAR DIAGNOSTIC CANCER TEST
SG11201403927XA (en) * 2012-01-13 2014-08-28 Genentech Inc Biological markers for identifying patients for treatment with vegf antagonists
EP2667193A1 (en) * 2012-05-23 2013-11-27 Université d'Aix-Marseille MMP2 as a predictive biomarker of response to antiangiogenic therapy and survival after therapy in cancer patients
JP2015536667A (en) * 2012-12-03 2015-12-24 アルマック・ダイアグノスティクス・リミテッドＡｌｍａｃ Ｄｉａｇｎｏｓｔｉｃｓ Ｌｉｍｉｔｅｄ Molecular diagnostic tests for cancer

Also Published As

Publication number Publication date
EP3149196A1 (en) 2017-04-05
US20170088902A1 (en) 2017-03-30
GB201409476D0 (en) 2014-07-09
WO2015181555A1 (en) 2015-12-03

Similar Documents

Publication Publication Date Title
MX2017008421A (en) Therapeutic, diagnostic and prognostic methods for cancer of the bladder.
MX2020008976A (en) Biomarkers and methods of treating pd-1 and pd-l1 related conditions.
MA39776A (en) Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
MX368099B (en) Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds.
MX2016012697A (en) Protein biomarker profiles for detecting colorectal tumors.
MX2020010947A (en) Methods of treating alzheimer's disease.
WO2014150751A3 (en) Biomarkers associated with brm inhibition
NZ703411A (en) Use of markers in the diagnosis and treatment of prostate cancer
EP2971132A4 (en) Tissue and blood-based mirna biomarkers for the diagnosis, prognosis and metastasis-predictive potential in colorectal cancer
WO2016066634A3 (en) Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer
WO2014078468A3 (en) Biomarkers for predicting clinical response of cancer patients to treatment with immunotherapeutic agent
TR201909951T4 (en) A method for predicting the outcome of aflibercept treatment of a patient suspected of having cancer.
WO2014205266A3 (en) Compositions and methods for detecting and treating glioblastoma
WO2017027391A3 (en) Genetic abnormalities in plasma cell dyscrasias
NZ729773A (en) Biomarkers for disease progression in melanoma
MA40636A (en) Methods of detecting prostate cancer
MX2016017097A (en) Biomarkers for response to ezh2 inhibitors.
WO2016133449A9 (en) Detection and treatment of malignant tumours in the cns
MX2020006388A (en) Biomarkers for diagnosis and prognosis of corneal ectatic disorders.
WO2015181555A8 (en) Expression profiling for determining the responsiveness of cancers to treatment with an anti-angiogenic agent
WO2014071218A3 (en) Biomarkers for breast cancer and methods of using same
WO2014107718A3 (en) Heat shock protein (hsp) inhibition and monitoring effectiveness thereof
WO2013132354A3 (en) Gene signatures associated with efficacy of postmastectomy radiotherapy in breast cancer
MX2017014540A (en) Biomarkers for a combination therapy comprising lenvatinib and everolimus.
WO2015036643A3 (en) Marker for predicting metastasis of breast cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15727055

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 15311618

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2015727055

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015727055

Country of ref document: EP